CKD to conduct Phase I trial for novel antidiabetic agent
Published: 2004-11-24 06:57:00
Updated: 2004-11-24 06:57:00
The Ministry of Health and Welfare said on November 22 that Chong Kun Dang Pharmaceutical Co. will conduct its Phase I trial for novel glitazone-based diabetes medication (code name: CKD-501) with the ministry's financial support of 740 million won for the recent five years.
Preclinical studie...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
